Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HiFiBiO Raises $75 Million for Clinical Trials and Drug Discovery

publication date: Jun 14, 2021

HiFiBiO, a US-China biotech, closed a $75 million Series D financing to support clinical trials of its two leading antibody therapies for oncology. HiFiBiO uses its proprietary single-B-cell functional antibody discovery platform, CelliGO™, to discover candidates. In addition to developing its own drugs, the company has formed several strategic discovery partnerships with pharmas and biotechs. The D round was led by new investor Mirae Asset, a global company. HiFiBiO is headquartered in Cambridge, Mass. with operations in Shanghai, Hangzhou, Paris and Hong Kong. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here